SCHEMBL5416207

SCHEMBL5416207

Oc1ccc2nc(-c3ccccc3O)sc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.69
▸ KDM4E B2RXH2 3/20 0.69
▸ NPC1 O15118 2/20 0.69
▸ RAB9A P51151 2/20 0.69
▸ NPSR1 Q6W5P4 1/20 0.69
▸ APP P05067 12/20 0.55
▸ SULT1A1 P50225 3/20 0.55
▸ GAA P10253 2/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ CASP1 P29466 1/20 0.52
▸ SNCA P37840 1/20 0.52
▸ CASP7 P55210 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13866532 0.87 KDM4E (0.56) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL13866522 0.86 RAB9A (0.58) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL5415895 0.85 MAPT (0.55) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL5415902 0.85 MAPT (0.55) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL1549967 0.85 KDM4E (0.76) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL8374081 0.85 KDM4E (0.76) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL13866510 0.85 RAB9A (0.57) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL2789423 0.84 MAPT (0.54) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL27648807 0.84 MAPT (0.67) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL2789030 0.83 PIK3CA (0.55) MAPTKDM4ENPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208066-A1 ER-beta-selective ligands BARLAAM BERNARD 2007-09-06 — — US disclosed
US-20060111408-A1 Therapeutic benzothiazole compounds BARLAAM BERNARD 2006-05-25 — — US disclosed
US-7045539-B2 Therapeutic benzoxazole compounds ASTRAZENECA AB (SE) 2006-05-16 — — US disclosed
US-20040102435-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2004-05-27 — — US disclosed
EP-1345914-A1 THERAPEUTIC COMPOUNDS AstraZeneca AB (SE) 2003-09-24 — — EP disclosed
WO-2002051821-A1 THERAPEUTIC COMPOUNDS ASTRAZENECA AB (SE) 2002-07-04 — — WO disclosed
EP-0483502-B1 High temperature resistant benzothiazol-groups containing polyarylether BASF AG (DE) 1995-11-22 — — EP disclosed
US-5227454-A HIGH TEMPERATURE RESISTANT, BENZOTHIAZOLE-CONTAINING POLYARYL ETHERS BASF AKTIENGESELLSCHAFT (DE) 1993-07-13 — — US disclosed
EP-0483502-A1 High temperature resistant benzothiazol-groups containing polyarylether BASF Aktiengesellschaft (DE) 1992-05-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102435-A1 Therapeutic compounds ESRRA, ESRRG, ESR2 MAPT 388/4885KDM4E 2759/4885NPC1 2588/4885
US-20070208066-A1 ER-beta-selective ligands ESR2, ESRRG, ESRRA MAPT 592/4885KDM4E 2761/4885NPC1 2976/4885
US-20060111408-A1 Therapeutic benzothiazole compounds ESR1, ESR2, ESRRG MAPT 221/4885KDM4E 1759/4885NPC1 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback